69627-02-7

Usage

Uses

Used in Pharmaceutical Industry:
THIENO[3,2-B]PYRIDIN-7-OL is used as a key intermediate in the synthesis of pharmaceuticals for its potential anti-inflammatory and anti-cancer properties. Its incorporation into drug formulations aims to develop treatments that can effectively combat inflammation and cancer cells.
Used in Agrochemical Industry:
In the agrochemical sector, THIENO[3,2-B]PYRIDIN-7-OL is utilized as a component in the development of pesticides and other agrochemical products. Its use is motivated by the need to create effective solutions for pest control and crop protection.
Used in Organic Chemistry Research:
THIENO[3,2-B]PYRIDIN-7-OL is employed as a valuable tool in organic chemistry research due to its unique structure and reactivity. It aids in the exploration of new chemical reactions and the synthesis of novel heterocyclic compounds.
Used in Drug Development:
As a building block in the production of heterocyclic compounds, THIENO[3,2-B]PYRIDIN-7-OL is instrumental in drug development. Its role is crucial for the advancement of new pharmaceuticals with potential therapeutic benefits.

Upstream product

• 90691-08-0 4,7-dihydro-7-oxothieno<3,2-b>-7(4H)pyridine-6-carboxylic acid 
• 17721-06-1 3-aminothiophene 
• 15568-86-2 5-(ethoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 2033-24-1 cycl-isopropylidene malonate 
• 108-20-3 di-isopropyl ether 
• 122-51-0 orthoformic acid triethyl ester 
• 31968-33-9 1-(3-amino-2-thienyl)ethanone 
• 109-94-4 formic acid ethyl ester 
• 1217903-01-9 3-[(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidenemethyl)amino]thiophene-2-carbaldehyde 
• 272-67-3 thieno[3,2-b]pyridine 
• 913377-45-4 2,2-dimethyl-5-{[(thiophen-3-yl)amino]methylidene}-1,3-dioxane-4,6-dione 
• 69626-98-8 6-ethoxycarbonylthieno<3,2-b>pyridin-7(4H)-one 

Downstream Products

• 69627-03-8 7-chlorothieno[3,2-b]pyridine 
• 104273-32-7 7-aminothieno<3,2-b>pyridine hydrate 
• 1228102-89-3 2-bromo-N-(3-(4-methoxybenzyloxy)phenyl)thieno[3,2-b]pyridin-7-amine 
• 1228102-90-6 4-(7-(3-(4-methoxybenzyloxy)phenylamino)thieno[3,2-b]pyridin-2-yl)benzaldehyde 
• 1228102-91-7 3-(7-(3-(4-methoxybenzyloxy)phenylamino)thieno[3,2-b]pyridin-2-yl)benzaldehyde 
• 1228103-34-1 N-(3-(4-methoxybenzyloxy)phenyl)-2-(4-(piperidin-1-ylmethyl)phenyl)thieno[3,2-b]pyridin-7-amine 
• 1228102-50-8 3-(2-(4-(piperidin-1-ylmethyl)phenyl)thieno[3,2-b]pyridin-7-ylamino)phenol trifluoroacetic acid 
• 1228103-41-0 N-(3-(4-methoxybenzyloxy)phenyl)-2-(3-(piperidin-1-ylmethyl)phenyl)thieno[3,2-b]pyridin-7-amine 
• 116538-95-5 thieno[3,2-b]pyridine-6-carbonitrile 
• 871690-72-1 3-fluoro-4-(thieno[3,2-b]pyridin-7-yloxy)aniline 
• 603305-89-1 7-bromothieno[3,2-b]pyridine 
• 866112-74-5 C₇H₄ClNOS 
• 866112-69-8 4-[2-hydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2-trifluoromethylpentyl]-4H-thieno[3,2-b]pyridin-7-one 
• 866112-67-6 4-[4-(5-fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-4H-thieno[3,2-b]pyridin-7-one 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

In our continuing efforts to develop novel c-Met inhibitors as potential anticancer candidates, a series of new N-sulfonylamidine derivatives were designed, synthesized via Cu-catalyzed multicomponent reaction (MCR) as the key step, and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (A549, HT-29, MKN-45 and MDA-MB-231). Most of the target compounds showed moderate to significant potency at both the enzyme-based and cell-based assay and possessed selectivity for A549 and HT-29 cancer cell lines. The preliminary SAR studies demonstrated that compound 26af (c-Met IC50 = 2.89 nM) was the most promising compound compared with the positive foretinib, which exhibited the remarkable antiproliferative activities, with IC50 values ranging from 0.28 to 0.72 μM. Mechanistic studies of 26af showed the anticancer activity was closely related to the blocking phosphorylation of c-Met, leading to cell cycle arresting at G2/M phase and apoptosis of A549 cells by a concentration-dependent manner. The promising compound 26af was further identified as a relatively selective inhibitor of c-Met kinase, which also possessed an acceptable safety profile and favorable pharmacokinetic properties in BALB/c mouse. The favorable drug-likeness of 26af suggested that N-sulfonylamidines may be used as a promising scaffold for antitumor drug development. Additionally, the docking study and molecular dynamics simulations of 26af revealed a common mode of interaction with the binding site of c-Met. These positive results indicated that compound 26af is a potential anti-cancer candidate for clinical trials, and deserves further development as a selective c-Met inhibitor.

Pyridine-thiophene-based diketopyrrolopyrrole and polymer thereof

The invention discloses a pyridine-thiophene-based diketopyrrolopyrrole polymer. The structure of the pyridine-thiophene-based diketopyrrolopyrrole polymer is shown as a formula I. The hole mobility of an organic field-effect transistor made from pyridine-thiophene-based diketopyrrolopyrrole serving as an organic semiconductor layer is 1.31*10cmVs, and the switching ratio is greater than 10 to 10; the pyridine-thiophene-based diketopyrrolopyrrole polymer has a very high application foreground in organic field-effect transistor devices. The formula (I) is shown in the description.

Polysubstituted quinolone compounds, and preparation method and use thereof

The invention provides polysubstituted quinolone compounds, and a preparation method and a use thereof, and concretely provides a polysubstituted quinolone compound represented by formula I, and optical isomers, pharmaceutically acceptable salts or solvates thereof. All groups in the formula I are defined in the description. The quinolone compound has excellent c-Met inhibition activity, and can be used for treating c-Met activity or expression level corrected diseases.

ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention is for the anti-inflammatory compounds that have an inhibitory activity against protein tyrosine kinases and their pharmaceutical composition(s) containing the compound as the active ingredient. Since the compounds of the present invention can inhibit multiple protein kinases associated with inflammatory diseases and immune disorders, they are useful for their prevention or treatment.

Cyclisation reactions of some pyridazinylimidoylketenes

Flash vacuum pyrolysis (FVP) of aminopyridazinone derivatives of Meldrum's acid at 600 °C (0.02 Torr) results in generation of an imidoylketene intermediate followed by cyclisation. In the case of the 5-amino derivatives, the products are pyrido[2,3-d]pyridazines, whereas the 4-amino compounds lead to mixtures of pyrido[2,3-d]pyridazines and pyrrolo[3,2-c]pyridazines. The feasibility of the 1,5-sigmatropic shift of a chlorine atom, required for the formation of two of the pyrido[2,3-d]pyridazines, was supported by the corresponding reaction of a corresponding 2,6-dichloroaniline derivative. The feasibility of the decarboxylation mechanism required for the formation of the pyrrolo[3,2-c]pyridazines, was supported by related processes in the FVP reactions of model compounds and by DFT calculations.

COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.

SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity

Novel classes of thienopyrimidines and thienopyridines have been identified as potent inhibitors of VEGFR-2 kinase. The synthesis and SAR of these compounds is presented, along with successful efforts to diminish EGFR activity present in the lead series.

Cross-coupling methods for the large-scale preparation of an imidazole - Thienopyridine: Synthesis of [2-(3-methyl-3H-imidazol-4-yl)-thieno[3,2-b]pyridin-7-yl] -(2-methyl-1H-indol-5-yl)-amine

The multihundred-gram synthesis of [2-(3-methyl-3H-imidazol-4-yl)-thieno[3,2-b]pyridin-7-yl] -(2-methyl-1H-indol-5-yl)-amine (1) is described utilizing a Stille cross-coupling of an iodothienopyridine (3) with 5-(tributylstannyl)-1-methylimidazole (11). Several cross-coupling methods were evaluated for the conversion of thienopyridine 3 to imidazole - thienopyridine 2, but only two were effective: the Stille coupling and a Negishi cross-coupling of the organozinc reagent derived from 2-(tertbutyldimethylsilyl)-1-methylimidazole and iodothienopyridine (3). The latter procedure worked well on laboratory scale (50 g), but was capricious upon scale-up. The issues with scale-up of an organostannane reagent are discussed, including control and analysis of organotin levels.

Thienopyrimidine and thienopyridine derivatives useful as anticancer agents

The invention relates to compounds of the formulas 1 and 2 and to pharmaceutically acceptable salts and hydrates thereof, wherein X1, R1, R2and R11are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas 1 and 2 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formulas 1 and 2.